Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HER2/neu expressing tumor~2. HLA-A2+ and/or HLA-A3+ to receive the vaccine. HLA-A2- and/or HLA-A3- patients will be eligible to be included in the control group.~3. Immunologically intact with a good performance status~4. Identified as being high or intermediate risk for recurrence~5. Without evidence of disease~6. Completion of all standard first-line therapies (but may still be on hormonal therapy)~Exclusion Criteria:~1. Tumor does not express HER2/neu~2. Not HLA-A2+ and/or HLA-A3+~3. Anergic~4. Receiving immunosuppressive therapy~5. In poor health (Karnofsky \<60%, ECOG \>2 and Tbili \>1.5 and creatinine\>2)~6. Pregnant (beta HCG+)~7. Metastatic disease or have refused standard therapies~8. Patients enrolled in other experimental protocols may enroll to this study only with the permission of the other study PI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E75 + GM-CSF vaccine (Type: EXPERIMENTAL): The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
- Control/observation (Type: NO_INTERVENTION): HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).